NCT06414356 · ClinicalTrials.gov record · last posted 2025-02-25
The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD
StatusRecruiting
PhasePhase 4
Started2024-10-02
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 25, 2025 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the \~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.
Amendment record
2 amendments on the ClinicalTrials.gov record
This ClinicalTrials.gov record has been amended 2 times since 2024-05-09; most recent amendment 2025-02-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history.
See every version on ClinicalTrials.gov ↗
2025-02-24
Status change Not Yet Recruiting→Recruitingv2
| NCT Number |
NCT06414356 |
| Lead Sponsor |
Margaux M. Salas, PhD
|
| Conditions |
Neuropathic Pain, PTSD |
| Enrollment |
30 participants |
| Start Date |
2024-10-02 |
| Primary Completion |
2025-04 (estimated) |
| Study Completion |
2027-05 (estimated) |
| Updated on ClinicalTrials.gov |
2025-02-25 |